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Background: An important subpopulation in allergic rhinitis is represented by patients with 
severe form of disease that is not responsive to drug treatment. It has been reported that grass 
pollen subcutaneous immunotherapy is effective in drug-resistant patients. In a real-life study, 
we evaluated the efficacy of 5-grass pollen tablets in patients with grass pollen-induced allergic 
rhinitis not responsive to drug therapy.
Methods: We carried out this multicenter observational study in adults and adolescents with 
grass-induced allergic rhinitis not responsive to drug therapy who were treated for a year with 
5-grass pollen tablets. Clinical data collected before and after sublingual immunotherapy (SLIT) 
included Allergic Rhinitis and its Impact on Asthma (ARIA) classification of allergic rhinitis, 
response to therapy, and patient satisfaction.
Results: Forty-seven patients entered the study. By ARIA classification, three patients had 
moderate to severe intermittent allergic rhinitis, ten had mild persistent allergic rhinitis, and 
34 had moderate to severe persistent allergic rhinitis. There were no cases of mild intermittent 
allergic rhinitis before SLIT. After SLIT, 33 patients had mild intermittent allergic rhinitis, 
none had moderate to severe intermittent allergic rhinitis, seven had mild persistent allergic 
rhinitis, and seven had moderate to severe persistent allergic rhinitis. The mean medication 
score decreased from 4.2±1.3 before to 2.4±2.0 after SLIT (P,0.01), representing a reduction 
of 42%. The response to treatment before SLIT was judged as poor by 70% of patients and very 
poor by 30%. Patient satisfaction was significantly increased after SLIT (P,0.01).
Conclusion: In real life, most patients with grass pollen-induced allergic rhinitis not respon-
sive to drug treatment can achieve control of the condition with one season of treatment using 
5-grass pollen tablets.
Keywords: grass pollen, rhinitis, drug resistance, allergen immunotherapy, effectiveness, 
patient satisfaction
Introduction
Allergen immunotherapy (AIT) is based on administration of increasing doses of 
the causal allergen to reduce clinical reactivity in allergic patients, and therefore is 
the only treatment targeting the cause and not merely the symptoms of respiratory 
 allergy.1 The outcome is achieved via the immunologic mechanism of action of AIT, 
that mostly consists of restoring a Th1-dominant T-cell response and generating 
specific T-suppressor cells.2 These effects are clinically expressed by tolerance to 
the administered allergen, resulting, as far as respiratory allergy is concerned, in a 
decreased burden of rhinitis and asthma.3 AIT may be administered via the injected 
route  (subcutaneous immunotherapy, SCIT) or the sublingual route (sublingual immu-
notherapy, SLIT). The efficacy of SLIT in allergic rhinitis and asthma is demonstrated 
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by a number of meta-analyses,4–10 including subpopula-
tions such as children,5,7 patients specifically evaluated for 
asthma,6 and patients treated with particular allergens such 
as the house dust mite9 or grass pollen.10 Another impor-
tant subpopulation is represented by patients inadequately 
controlled on drug treatment, who have severe symptoms 
during the pollen season and consequently a high burden of 
disease and high economic costs.11
Frew et al were the first to show that one season of SCIT 
was significantly more effective than placebo with regard 
to symptoms and medication scores in patients with grass 
pollen-induced rhinoconjunctivitis who had had an unsatis-
factory response to standard drug treatment.12 In their study, 
two maintenance doses of 10,000 and 100,000 standardized 
quality (SQ) units were used, with higher efficacy but also 
lower tolerability using the higher dose. It is well known that 
SLIT is significantly better tolerated than SCIT, but no trials 
are available showing that SLIT is effective in patients not 
adequately controlled by drugs. A recent post hoc analysis 
of published studies using 5-grass pollen tablets showed that 
better clinical efficacy was achieved by immunotherapy in 
patients with more severe allergic rhinitis, although it was 
not reported if these patients were unresponsive to drugs.13 
In a real-life study, we evaluated the efficacy of SLIT using 
5-grass pollen tablets in patients poorly responsive to drug 
treatment.
Materials and methods
Patients
Seven allergy centers in Italy, namely Niguarda Hospital 
(Milan), San Marco General Hospital (Bergamo), Treviglio 
Hospital (Bergamo), Italian Institute for Auxology (Milan), 
Maggiore General Hospital (Milan), Riuniti Hospital 
 (Bergamo), and Legnano Hospital (Milan) participated 
in this study. Male and female subjects aged 12–45 years 
with seasonal allergic rhinitis were included. For inclusion, 
patients had to have had symptoms of rhinitis during the 
grass pollen season (from mid April to end of June) for 
at least 2 consecutive years, an unsatisfactory response to 
drug treatment in the previous season, as assessed by the 
patients themselves using a specific questionnaire, and a 
positive skin prick test with grass pollen extracts.  Allergic 
rhinitis was classified according to Allergic Rhinitis and 
its Impact on Asthma (ARIA) guidelines.3 The main exclu-
sion criteria were allergic rhinoconjunctivitis caused by 
cosensitization and likely to influence symptoms during 
the study, previous AIT, and the usual contraindications 
to AIT.14
study design
This multicenter observational study, known as ORS 
(Oralair® Rhinitis Solution, Stallergenes, Antony, France) 
was conducted in two phases: at the end of the 2010 pollen 
season, the investigators identified patients with allergic 
rhinitis unresponsive to drug therapy (retrospective phase); 
and during the 2011 pollen season collected clinical data 
from these patients, who were treated preseasonally and 
coseasonally with 5-grass pollen tablets (prospective phase). 
Medication scores in the two seasons were calculated by 
attributing a score of 3 to topical steroids, a score of 2 to oral 
antihistamines or antileukotrienes, and a score of 1 to topical 
antihistamines or nasal decongestants.
The primary objective of the study was to investigate the 
effectiveness of first-year SLIT treatment in patients with 
allergic rhinitis unresponsive to drug treatment. The second-
ary objectives were to assess use of rescue medication, the 
presence of comorbidities, and patient satisfaction, measured 
using a visual analog scale that has been proven to be a valid 
tool in evaluating allergic rhinitis,15 in particular for patient 
satisfaction.16 Using the visual analog scale, patients assessed 
their level of satisfaction by indicating a position along a 
continuous line between two points from 0 (very dissatisfied) 
to 10 (very satisfied).
For data collection, we used a paper case report form 
recording the ARIA classification of allergic rhinitis,3 onset 
of symptoms, clinically relevant allergen(s), comorbidities, 
response to therapy, and patient satisfaction.
Written informed consent was obtained before entering 
the study, and in the case of minors was obtained from next 
of kin, caregivers, or guardians. The study was conducted in 
accordance with good clinical practice guidelines. The ethics 
committees at each of the participating sites approved the 
study, ie, the ethics committees of Niguarda Hospital (Milan), 
San Marco General Hospital (Bergamo), Treviglio Hospital 
(Bergamo), Italian Institute for Auxology (Milan), Maggiore 
General Hospital (Milan), Riuniti Hospital (Bergamo), and 
Legnano Hospital (Milan).
immunotherapy
SLIT was performed using a preparation of 5-grass pollen 
in tablets (Oralair®; Stallergenes S.A., Antony, France), the 
characteristics of which have already been reported.17 Briefly, 
the preparation contains a mixture of Phleum pratense, Dac-
tylis glomerata, Anthoxanthum odoratum, Lolium perenne, 
and Poa pratensis, covering the immunoglobulin E sensitiza-
tion profiles of grass-allergic patients in the Mediterranean 
area.18 Each tablet was taken sublingually once daily in the 
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morning before breakfast and was kept under the tongue until 
complete dissolution before swallowing. It was administered 
according to a pre-coseasonal schedule of SLIT, ie, started 
4 months before the expected start of the grass pollen season 
and stopped at the end of the pollen season, for an overall 
duration of 6 months. Any local or systemic adverse effects 
of SLIT were to be recorded by the patients.
statistical analysis
A central organization (IBIS Informatica, Milan, Italy) 
undertook the data entry and statistical analysis. Nominal 
and discrete parameters were reported as contingency 
tables  (frequency and percentage). McNemar’s test was 
used to compare the two pollen seasons (2010 versus 2011). 
 Continuous parameters were reported as the frequency, mean, 
standard deviation, median, first and third quartile, and mini-
mum and maximum. Comparison of the two pollen seasons 
was performed using the Student’s t-test for paired data, and 
the difference between seasons was reported with the related 
95% confidence interval. Inferential tests were evaluated at a 
5% level of significance. Statistical analysis was carried out 
using BMDP Dynamic 2009 version 8.2 software (BMDP 
Statistical Software, Inc., Los Angeles, CA, USA).
Results
Forty-seven patients of mean age 25.7 years were included 
in the study, comprising 23 males and 24 females, with 
38 adults and nine adolescents. Allergic rhinitis had been 
present for 12±8.5 years in the adults and for 5.5±4.2 years 
in the adolescents. Of the 47 patients, at inclusion in 2010, 
none (0%) reported mild intermittent allergic rhinitis, 
three (6.4%) had moderate to severe intermittent allergic 
rhinitis, ten (21.3%) had mild persistent allergic rhinitis, 
and 34 (72.3%) had moderate to severe persistent allergic 
rhinitis. The response to symptomatic treatment was judged 
as poor by 33 patients (70.2%) and very poor by 14 patients 
(29.8%). During the 2011 grass pollen season, after treatment 
with 5-grass pollen tablets, 33 patients (79.2%) reported mild 
intermittent allergic rhinitis, none (0%) had moderate to 
severe intermittent allergic rhinitis, seven (14.9%) had mild 
persistent allergic rhinitis, and seven (14.9%) had moderate 
to severe persistent allergic rhinitis.
Comparing the two seasons, 31 patients classified as hav-
ing mild or moderate to severe persistent disease when treated 
with symptomatic drugs changed to mild intermittent allergic 
rhinitis when treated with 5-grass pollen tablets (P,0.01). 
Figure 1 shows the changes in ARIA classification for the two 
seasons. All patients were sensitized to grass pollen. Among the 
adolescents, six were monosensitized and three were also sen-
sitized to the house dust mite. Adults showed a number of other 
sensitizations, ie, house dust mite in 11 patients, olive pollen 
in seven, birch pollen in six, cypress pollen in four, Parietaria 
pollen in four, and ragweed pollen in three patients.
Table 1 shows the comorbidities reported by patients, the 
most common being conjunctivitis and asthma. The mean 
medication score changed from 4.2±1.3 before to 2.4±2.0 
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Figure 1 ARIA classification of allergic rhinitis before and after treatment with 5-grass pollen tablets.
Abbreviations: AriA, Allergic rhinitis and its impact on Asthma; sliT, sublingual immunotherapy.
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Figure 2 Medication score before and after treatment with 5-grass pollen tablets. The medication score in the 2011 pollen season was significantly lower than in the 2010 
pollen season (mean difference −1.8, 95% confidence interval −2.1 to −1.5, P,0.01).
Abbreviation: sliT, sublingual immunotherapy.
Table 1 Assessment of comorbidities in study population
Comorbidity Adults  
(n=38)
Adolescents  
(n=9)
Total  
(n=47)
n (%) n (%) n (%)
sinusitis 0 (0.0) 0 (0.0) 0 (0.0)
conjunctivitis 26 (68.4) 8 (88.9) 34 (72.3)
Asthma 19 (50.0) 0 (0.0) 19 (40.4)
Turbinate hypertrophy 2 (5.3) 0 (0.0) 2 (4.3)
Polyposis 0 (0.0) 0 (0.0) 0 (0.0)
sleep disturbance 0 (0.0) 0 (0.0) 0 (0.0)
Others 4 (10.5) 0 (0.0) 4 (8.5)
after SLIT (P,0.01), representing a decrease of 42% 
 (Figure 2). Twelve patients did not use any rescue medica-
tion during treatment with SLIT. In particular, a significant 
decrease was found in the use of oral antihistamines (46.8%) 
and nasal decongestants (21.3%). Also, concerning the con-
sumption of drugs for asthma, a decrease, albeit not signifi-
cant, was found, corresponding to 6.4% for both β2-agonists 
and inhaled corticosteroids. The mean visual analog score for 
patient satisfaction increased from 3±1.3 before to 8.7±1.3 
after SLIT, indicating a significant improvement (P,0.01, 
Figure 3).
Discussion
Patients with severe allergic rhinitis warrant particular 
attention. A definition of severe chronic upper airway dis-
ease has been introduced to identify those patients whose 
symptoms are inadequately controlled despite adequate 
pharmacologic treatment based on guidelines, and thus have 
impaired quality of life, social functioning, sleep, and school/
work performance.19 A recent reappraisal of the current status 
of knowledge on severe chronic upper airway disease listed 
a need for “… defining success of medical treatment includ-
ing immunotherapy in terms of control in allergic rhinitis”.20 
However, thus far, only one study has addressed this issue. 
In a large study of patients with grass pollen-induced allergic 
rhinitis not controlled by standard drug treatment, 203 were 
randomized to maintenance with 100,000 SQ units, 104 to 
10,000 SQ units, and 103 to placebo, with both active treat-
ments being significantly more efficacious than placebo. 
The 100,000 SQ unit regimen was more effective, but the 
10,000 SQ unit regimen caused fewer side effects.12 It is sur-
prising that no other study has been done in this area, either 
with SCIT or SLIT, that has the advantage of being much 
better tolerated.21 In addition, SLIT meets the requirements 
for use as treatment for pollen-allergic patients because it 
has the highest evidence of efficacy as demonstrated by 
meta-analyses4–8,10 and offers benefit over SCIT in terms of 
compliance and pharmacoeconomic aspects.22
In a real-life study, we sought to assess the effectiveness 
of SLIT in the form of the 5-grass pollen preparation in drug-
resistant patients, given that this therapy has already been 
demonstrated to be effective and safe in both adults17 and 
children.23 The 5-grass pollen tablets were prescribed after 
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a pollen season in which standard drug treatment, ie, anti-
histamines, nasal corticosteroids, and nasal decongestants, 
had been ineffective. Following 5-grass pollen therapy, the 
clinical stage of allergic rhinitis, as defined by ARIA clas-
sification, was overturned. The number of patients with mild 
intermittent allergic rhinitis increased from 0 to 33, while 
the number of patients with moderate to severe persistent 
allergic rhinitis decreased from 34 to 7, ie, the severity of 
symptoms was reversed. Mean medication scores decreased 
significantly from 4.2±1.3 before to 2.4±2.0 after SLIT. This 
finding indicates that 5-grass pollen tablets are able to achieve 
clinical control of allergic rhinitis in patients unresponsive to 
drugs, as previously demonstrated for SCIT.12 Asthma was 
not a major issue for our patients, but a decrease in use of 
bronchodilators and inhaled corticosteroids was found with 
SLIT. This is not unexpected, given the strong relationship 
between allergic rhinitis and asthma.3 As far as factors related 
to failure of antiallergic drugs are concerned, a recent paper 
on severe chronic upper airway disease suggested a number 
of disease-related, patient-related, and treatment-related 
 factors.20 Among them, comorbidities, such as chronic sinus-
itis, and adherence to medical treatment seem particularly 
important. We can exclude a role for comorbidity in our 
population, because no patient reported sinusitis. On the other 
hand, it is well known that adherence is a major problem in 
treating allergic rhinitis.24,25
The patients in our study reported having been adher-
ent with their prescribed drug treatment, but no stringent 
method of control, such as counting the assumed drug doses 
or frequent phone calls, was used. In any case, it is unlikely 
that patients with symptoms unresponsive to drugs, ie, the 
type of population we targeted, use less than the optimal dose 
recommended by their physicians. In fact, in a recent Italian 
survey of 1,379 patients with allergic rhinitis undertaken by 
107 general practitioners, adherence with ARIA guidelines 
was evaluated according to severity classification, and adher-
ence was observed to increase according to the severity of 
the condition. In particular, adherence was satisfactory in 
patients with moderate to severe persistent allergic rhinitis, 
with a rate of 89% for those with allergic rhinitis alone and 
95% for those with allergic rhinitis and asthma. The authors 
concluded that adherence to ARIA guidelines is satisfactory 
only in patients with more severe disease.26
It is of particular interest to focus on the relevance of drug 
resistance in patients with allergic rhinitis. To the best of our 
knowledge, only one study that included an epidemiologic 
assessment is available, and showed that 111 (13.9%) of 
796 patients had uncontrolled allergic rhinitis after treat-
ment. The evaluation included a number of parameters, 
including total symptom scores for rhinitis, a visual analog 
scale, the Rhinoconjunctivitis Quality of Life Questionnaire, 
and the Allergy-specific Work Productivity and Impairment 
 Questionnaire. A cluster-randomized trial model was used to 
mimic real life, with no exclusion of patients at randomiza-
tion, so as to include the broad range of patients regularly 
seen by physicians.27
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Figure 3 Patient satisfaction before and after treatment with 5-grass pollen tablets. Patient satisfaction in 2011 pollen season was significantly higher than in the 2010 pollen 
season (mean difference −5.72, 95% confidence interval −6.33 to −5.12, P,0.01).
Abbreviation: sliT, sublingual immunotherapy.
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Concerning patient satisfaction with treatment, it is rea-
sonable to assume that this is related to clinical outcome. 
Recent studies have investigated patient satisfaction with 
treatment for allergic rhinitis and allergic asthma. In a survey 
conducted in 21 allergy centers in Italy, only 33.5% of patients 
with allergic rhinitis and 40.7% of patients with asthma were 
satisfied with their symptomatic treatment. The main factors 
associated with treatment dissatisfaction were female gender, 
comorbidity, and the severity of symptoms of allergic rhinitis 
and asthma.28 Similar results were reported in a survey of more 
than 5,000 patients in Europe, with one third being dissatisfied 
with the treatment prescribed.29 In our study, all patients were 
dissatisfied with their medical treatment because nonrespon-
siveness to drugs was an inclusion criterion. However, the level 
of satisfaction, as measured by the visual analog scale, was 
very low with drugs but increased significantly with SLIT.
Conclusion
In the present real-life study, we found that most patients 
with grass pollen-induced allergic rhinitis who did not 
respond to drug treatment achieved control of their aller-
gic rhinitis using pre-coseasonal treatment with 5-grass 
pollen tablets during a one-year period. This finding now 
needs to be confirmed by randomized controlled trials 
targeting this important subpopulation of patients with 
allergic rhinitis.
Disclosure
FF, IDA, and PP are employees of Stallergenes Italy.  CI is a 
scientific consultant for Stallergenes Italy. The other authors 
have no conflicts of interest that are directly relevant to the 
content of this study.
References
1. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, 
Demoly P. Allergen-specific immunotherapy for respiratory allergies: 
from meta-analysis to registration and beyond. J Allergy Clin Immunol. 
2011;127(1):30–38.
2. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific 
immunotherapy. Allergy. 2011;66(6):725–732.
3. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact 
on Asthma (ARIA) 2008 update (in collaboration with the World Health 
Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86: 
8–160.
4. Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy 
for allergic rhinitis: systematic review and meta-analysis. Allergy. 
2005;60(1):4–12.
5. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen 
vaccination for respiratory allergy in children. Conclusions from one 
meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16.
6. Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the 
efficacy of sublingual immunotherapy in the treatment of allergic 
asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3): 
599–609.
 7. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual 
immunotherapy in the treatment of allergic rhinitis in pediatric patients 
3–18 years of age: a meta analysis of randomized placebo-controlled, 
double blind trials. Ann Allergy Asthma Immunol. 2006;97(2): 
141–148.
 8. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual 
immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 
2010;12:CD002893.
 9. Compalati E, Passalacqua G, Bonini M, Canonica GW. The effi-
cacy of sublingual immunotherapy for house dust mites respiratory 
allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11): 
1570–1579.
 10. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy 
of sublingual immunotherapy with grass allergens for seasonal allergic 
rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 
2010;126(3):558–566.
 11. Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass 
pollen tablets versus placebo in the treatment of allergic rhinitis in 
adults. Clin Drug Investig. 2013;33(5):343–349.
 12. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy 
Study Group. Eff icacy and safety of specif ic immunotherapy 
with SQ allergen extract in treatment-resistant seasonal allergic 
rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(2):319–325.
 13. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen 
immunotherapy studies shows increased clinical efficacy in highly 
symptomatic patients. Allergy. 2012;67(3):321–327.
 14. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: 
therapeutic vaccines for allergic diseases. A WHO position paper. 
J Allergy Clin Immunol. 1998;102(4 Pt 1):558–562.
 15. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual 
analogue scale in patients treated for allergic rhinitis: an observational 
prospective study in primary care, asthma and rhinitis. Clin Exp Allergy. 
2013;43(8):881–888.
 16. Baiardini I, Puggioni F, Menoni S, et al. Patient knowledge, percep-
tions, expectations and satisfaction on allergen-specific immunotherapy: 
a survey. Respir Med. 2013;107(3):361–367.
 17. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety 
of once daily sublingual immunotherapy with a 5-grass pollen tablet 
for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6): 
1338–1345.
 18. Marcucci F, Sensi L, Di Cara G, et al. Which allergen extract for grass 
pollen immunotherapy? An in vitro study. Immunol Invest. 2010;39(6): 
635–644.
 19. Bousquet J, Bachert C, Canonica GW, et al. Unmet needs in severe 
chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 
2009;124(3):428–433.
 20. Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic 
rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 
2013;68(1):1–7.
 21. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The 
safety of sublingual-swallow immunotherapy: an analysis of published 
studies. Clin Exp Allergy. 2005;35(5):565–571.
 22. Incorvaia C, Masieri S, Scurati S, Soffia S, Puccinelli P, Frati F. The 
current role of sublingual immunotherapy in the treatment of allergic 
rhinitis in adults and children. J Asthma Allergy. 2011;4:13–17.
 23. Wahn U, Tabar A, Kuna P, et al; SLIT Study Group. Efficacy and safety 
of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic 
rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160–166.
 24. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in 
Europe: findings from a cross-sectional questionnaire survey. Allergy. 
2007;62(9):1057–1063.
 25. Bukstein D, Luskin AT, Farrar JR. The reality of adherence to rhinitis 
treatment: identifying and overcoming the barriers. Allergy Asthma 
Proc. 2011;32(4):265–271.
 26. Maio S, Simoni M, Baldacci S, et al. The ARGA study with Italian 
general practitioners: prescriptions for allergic rhinitis and adherence 
to ARIA guidelines. Curr Med Res Opin. 2012;28(10):1743–1751.
Journal of Asthma and Allergy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-asthma-and-allergy-journal
The Journal of Asthma and Allergy is an international, peer-reviewed 
open-access journal publishing original research, reports, editorials 
and commentaries on the following topics: Asthma; Pulmonary physi-
ology; Asthma related clinical health; Clinical immunology and the 
immunological basis of disease; Pharmacological interventions and 
new therapies. Issues of patient safety and quality of care will also be 
considered. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is all 
easy to use. Visit http://www.dovepress.com/testimonials.php to read 
real quotes from published authors.
Journal of Asthma and Allergy 2013:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
133
5-grass pollen tablets for seasonal allergic rhinitis
 27. Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic 
rhinitis during treatment and its impact on quality of life: a cluster 
randomized trial. J Allergy Clin Immunol. 2010;126(3):666–668.
 28. Ciprandi G, Incorvaia C, Scurati S, et al. Patient-related factors in rhinitis 
and asthma: the satisfaction with allergy treatment survey. Curr Med 
Res Opin. 2011;27(5):1005–1011.
 29. Chivato T, Valovirta E, Dahl R, et al. Allergy, living and learning: 
diagnosis and treatment of allergic respiratory diseases in Europe. 
J Investig Allergol Clin Immunol. 2012;22(3):168–179.
